Pharm
Stibogluconate
search
Stibogluconate
, Sodium Stibogluconate, Sodium Antimony Gluconate
See Also
Leishmaniasis
Meglumine Antimoniate
Background
Sodium Stibogluconate has been discontinued worldwide and is no longer available
Use
Meglumine Antimoniate
(
Glucantime
) instead
Indications
Leishmaniasis
Mechanism
Antimony (Sb) based
Antiprotozoal
with activity against
Leishmaniasis
Prodrug, reduced from pentavalent to trivalent form, interferes with
Protozoa
l metabolic pathways
Interacts with
Protozoa
l trypanothione (thiol group) critical for its
Redox Reaction
s
Disrupts cellular processes resulting in cellular death
Dosing
Precautions
Dilute intravenous doses in 50 ml D5W or NS prior to administration
Administer over >=10 minutes
Cutaneous Leishmaniasis
Stibogluconate
Sodium
(Pentostam) 20 mg/kg/day for 20 days
Visceral Leishmaniasis
Initial Course
Adult: 10 mg/kg IV/IM daily for 20-30 days
Child: 20 mg/kg IV/IM daily for 20-30 days
Relapse
Treat for 40-60 days
Adverse Effects
Common
Fatigue
and malaise
Headache
Gastrointestinal (
Nausea
,
Anorexia
, abominal pain)
Associated Lab abnormalities (see monitoring below)
Hepatic transaminase increase (AST, ALT)
Serum
Lipase
(and Amylase) increased
Cytopenia
EKG abnormalities (
QTc Prolongation
)
Safety
Pregnancy
Avoid in pregnancy (suspected to be
Teratogen
ic)
Lactation
Likely safe in
Lactation
given low milk concentrations
Consider avoiding
Breast Feeding
young infants (age <2 months) while taking
Meglumine Antimoniate
Monitoring: Baseline and weekly labs
Serum Creatinine
Liver Function Test
s
Serum
Lipase
or amylase
Complete Blood Count
Electrocardiogram
Resources
Glucantime
Drug Profile (ASTMH)
https://www.astmh.org/getmedia/35e1061e-82f7-4fc2-b05b-e3845e5aad8f/Glucantime-Drug-Profile.pdf
References
Freedman (2025) Sanford Guide, accessed 7/13/2025 on IOS
Type your search phrase here